Apnea of prematurity and caffeine pharmacokinetics: Potential impact on hospital discharge

Journal of Perinatology

Volumn 36, Issue 2, 2016, Pages 141-144

  Doyle, J ^a   Davidson, D ^a   Katz, S ^a   Varela, M ^b   Demeglio, D ^a   DeCristofaro, J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b Renaissance School of Medicine at Stony Brook University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE CITRATE; ADENOSINE RECEPTOR BLOCKING AGENT; CAFFEINE;

ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; FEMALE; GESTATIONAL AGE; HOSPITAL DISCHARGE; HUMAN; INFANT; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; NEWBORN APNEA; PLASMA HALF LIFE; PREMATURITY; TREATMENT DURATION; TREATMENT OUTCOME; APNEA; BLOOD; DRUG MONITORING; HALF LIFE TIME; INFANT, NEWBORN, DISEASES; NEWBORN; OUTCOME ASSESSMENT; PROCEDURES; STANDARDS; TIME FACTOR; TREATMENT WITHDRAWAL;

APNEA; CAFFEINE; DRUG MONITORING; FEMALE; GESTATIONAL AGE; HALF-LIFE; HUMANS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INFANT, PREMATURE; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DISCHARGE; PURINERGIC P1 RECEPTOR ANTAGONISTS; TIME FACTORS; WITHHOLDING TREATMENT;

EID: 84956688602     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2015.167     Document Type: Article

References (21)

1. Lodha A, Seshia M, McMillan DD, Barrington K, Yang J, Lee SK et al. Association of early caffeine administration and neonatal outcomes in very preterm neonates. JAMA Pediatr 2015; 169(1): 33-38.
2. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A et al. Caffeine therapy for apnea of prematurity. N Engl J Med 2006; 354(20): 2112-2121.
3. Eichenwald EC, Aina A, Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24 to 28 weeks. Pediatrics 1997; 100(3 Pt 1): 354-359.
4. Merritt TA, Pillers D, Prows SL. Early NICU discharge of very low birth weight infants: a critical review and analysis. Semin Neonatol 2003; 8(2): 95-115.
5. Ramanathan R, Corwin MJ, Hunt CE, Lister G, Tinsley LR, Baird T et al. Cardiorespiratory events recorded on home monitors: comparison of healthy infants with those at increased risk for SIDS. JAMA 2001; 285(17): 2199-2207.
6. Charles BG, Townsend SR, Steer PA, Flenady VJ, Gray PH, Shearman A. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit 2008; 30(6): 709-716.
7. Natarajan G, Botica ML, Thomas R, Aranda JV. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics 2007; 119(5): 936-940.
8. Leon AE, Michienzi K, Ma CX, Hutchison AA. Serum caffeine concentrations in preterm neonates. Am J Perinatol 2007; 24(1): 39-47.
9. Winter ME. Basic Clinical Pharmacokinetics. Lippincott Williams & Wilkins: Philadelphia, 2004.
10. Darnall RA, Kattwinkel J, Nattie C, Robinson M. Margin of safety for discharge after apnea in preterm infants. Pediatrics 1997; 100(5): 795-801.
11. Aranda JV, Beharry K, Valencia GB, Natarajan G, Davis J. Caffeine impact on neonatal morbidities. J Matern Fetal Neonatal Med 2010; 23(Suppl 3): 20-23.
12. Davis PG, Schmidt B, Roberts RS, Doyle LW, Asztalos E, Haslam R et al. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. J Pediatr 2010; 156(3): 382-387.
13. Le Guennec JC, Billon B, Pare C. Maturational changes of caffeine concentrations and disposition in infancy during maintenance therapy for apnea of prematurity: influence of gestational age, hepatic disease, and breast-feeding. Pediatrics 1985; 76(5): 834-840.
14. Alur P, Bollampalli V, Bell T, Hussain N, Liss J. Serum caffeine concentrations and short-term outcomes in premature infants of 29 weeks of gestation. J Perinatol 2015; 35: 434-438.
15. Comer AM, Perry CM, Figgitt DP. Caffeine citrate: a review of its use in apnoea of prematurity. Paediatr Drugs 2001; 3(1): 61-79.
16. Aldridge A, Aranda JV, Neima AH. Caffeine metabolism in the newborn. Clin Pharmacol Ther 1979; 4: 447-453.
17. Amin SB, Burnell E. Monitoring apnea of prematurity: validity of nursing documentation and bedside cardiorespiratory monitor. Am J Perinatol 2013; 30(8): 643-648.
18. Di Fiore JM, Arko MK, Miller MJ, Krauss A, Betkerur A, Zadell A et al. Cardiorespiratory events in preterm infants referred for apnea monitoring studies. Pediatrics 2001; 108(6): 1304-1308.
19. Subhani M, Katz S, DeCristofaro JD. Prediction of postdischarge complications by predischarge event recordings in infants with apnea of prematurity. J Perinatol 2000; 20(2): 92-95.
20. Ho T, Dukhovny D, Zupancic JAF, Goldmann DA, Horbar JD, Pursley DM. Choosing wisely in newborn medicine: five opportunities to increase value. Pediatrics 2015; 136(2): e482-e489.
21. Haddad W, Sajous C, Hummel P, Guo R. Discontinuing caffeine in preterm infants at 33-35 weeks corrected gestational age: failure rate and predictive factors. J Neonatal Perinatal Med 2015; 8(1): 41-45.